Today: 17 May 2026
TQQQ Is Back in Focus as Filings Reveal Bigger Bets on Leveraged Nasdaq ETF

TQQQ Is Back in Focus as Filings Reveal Bigger Bets on Leveraged Nasdaq ETF

New York, April 20, 2026, 14:38 EDT

Between April 18 and April 20, three reports relying on the latest 13F filings found that money managers boosted their holdings in ProShares UltraPro QQQ during the fourth quarter. Oriental Harbor Investment Master Fund took the most aggressive stance, raising its position to 2.40 million shares—about $126.6 million in value. Q3 Asset Management and Main Street Group wrapped up the period with 234,413 shares and 113,470 shares, respectively.

Though the positions were set up months back, the filings surfaced just as the Nasdaq pulled away from its peak. By late morning Monday, the index slipped 0.55%. Fresh U.S.-Iran strains weighed, coming despite global investors adding a net $28 billion to U.S. stocks since right before the ceasefire announcement.

Institutional managers with over $100 million in reportable securities must file a Form 13F with the SEC every quarter. TQQQ, a leveraged ETF, aims for triple the daily move of the Nasdaq-100 before fees and expenses by using derivatives. According to ProShares, those returns can swing well above or below that target over longer stretches.

Oriental Harbor went big, snapping up 1,200,820 more shares in the fourth quarter. That move brought its total to 2,401,640 shares—enough to make TQQQ the fund’s third-largest holding, representing roughly 9.6% of the overall portfolio, according to the filing summaries.

Q3 Asset Management took a sharper leap percentage-wise, bumping its TQQQ stake up 353.5% after snapping up 182,719 more shares. That pushed the position to roughly $12.36 million, now ranking fourth among the firm’s top holdings. Over at Main Street Group, the move was tamer but still notable—the firm lifted its stake by 82.1%, picking up 51,168 shares for a total around $5.98 million.

TQQQ is hardly a lightweight—ProShares reports net assets at roughly $31.6 billion and a market price pegged at $58.59 on April 17. Nvidia, Apple, Microsoft, and Amazon make up some of the fund’s largest holdings. Investors looking for a twist on that index can check out ProShares’ QLD, which offers 2x bullish exposure; SQQQ, on the other hand, gives a -3x leveraged play for the bears.

It’s part of a wider move back into U.S. risk assets. Since the ceasefire was announced, global investors poured a net $28 billion into U.S. equities. Leveraged ETFs, according to Nomura, scooped up another $27.5 billion in equities over the past week. But systematic positioning, says strategist Joanna Wang, is still “historically light.” Reuters

The trade can reverse quickly. ProShares cautions that TQQQ isn’t designed to achieve triple the Nasdaq-100’s return beyond a single day. Morningstar ETF analyst Bryan Armour, commenting earlier this year, called out the surge in leveraged product launches as evidence of a “growing reliance on speculation.” ProShares

Some bullish voices are bracing for a breather. Victoria Fernandez, chief market strategist at Crossmark Global Investments, called Monday’s dip “not surprising” given last week’s strong rally. With Tesla and other major U.S. names reporting earnings this week, she said, the appetite for tech faces a real test. Reuters

Stock Market Today

  • Aquestive Therapeutics Reports Strong Q1 Results, Analysts Maintain 2026 Forecasts
    May 16, 2026, 8:17 PM EDT. Aquestive Therapeutics (NASDAQ:AQST) posted strong first-quarter results with revenues of $14 million, surpassing analyst expectations by 33%, and smaller-than-expected losses of $0.07 per share. Despite the upbeat quarter, analysts forecast a 3.6% revenue decline in 2026 to $48.4 million and a 15% decrease in losses to $0.47 per share. The consensus price target remains steady at $8.89, suggesting the stock is trading in line with expectations amid continuing losses. Revenue growth is expected to slow significantly compared to the past five years, lagging behind an 8% annual growth forecast for the wider industry. Investors face mixed views on valuation, with targets ranging from $6.00 to $11.00 per share.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset
Previous Story

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Meta Q1 2026 Earnings Set for April 29 as Ad Growth Faces AI Spending Test
Next Story

Meta Q1 2026 Earnings Set for April 29 as Ad Growth Faces AI Spending Test

Go toTop